Research Papers:
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1473 views | HTML 2525 views | ?
Abstract
Mileidys Pérez-Alea1, Ana Vivancos2, Ginevra Caratú2, Judit Matito2, Berta Ferrer1,3, Javier Hernandez-Losa3, Javier Cortés4, Eva Muñoz1,4, Vicente Garcia-Patos1,5, Juan A. Recio1
1Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Oncology Program, Vall d’Hebron Research institute, VHIR-Vall d’Hebron Hospital, Barcelona-UAB 08035, Barcelona, Spain
2Cancer Genomics Group Translational Research Program, Vall d’Hebron Institute of Oncology-VHIO, Vall d’Hebron Hospital, Barcelona-UAB, Barcelona 08035, Spain
3Anatomy Pathology Department, Vall d’Hebron Hospital, Barcelona-UAB, Barcelona 08035, Spain
4Clinical Oncology Program, Vall d’Hebron Institute of Oncology-VHIO, Vall d’Hebron Hospital, Barcelona-UAB, Barcelona 08035, Spain
5Dermatology Department, Vall d’Hebron Hospital, Barcelona-UAB, Barcelona 08035, Spain
Correspondence to:
Juan A. Recio, email: [email protected]
Keywords: melanoma, blue nevus, GNAQ, BAP1, genetic profile
Received: January 25, 2016 Accepted: March 28, 2016 Published: April 4, 2016
ABSTRACT
Melanomas arising in association with a common or cellular blue nevus (MABN) comprise a relatively rare and heterogeneous group of lethal melanomas. Although GNAQ is known to be frequently mutated in common blue nevus, cellular blue nevus (CBN) and MABN and these malignant lesions present gross chromosome alterations harboring BAP1 mutations, little is known about other mutations that contribute to the development and progression of these neoplasms. Thus, the genetic profile of these tumors is important to increase the number of intervention and treatment modalities. Here, we characterized and genetically profiled two different sections of a rare MABN and two CBNs from three different patients. All of the samples harbored a GNAQ mutation, exhibited RAS pathway activation, and harbored additional mutations in genes associated with genomic instability and epigenetic regulation (KMT2C, FANCD2, ATR, ATRX, NBN, ERCC2, SETD2, and WHSC1). In addition, all neoplasms harbored mutations that directly or indirectly affected either the regulation or activation of the PI3K pathway (PIK3CA, NF1, INPP5B and GSK3B). Our results not only help understand the genetic complexity of these blue melanocytic lesions but provide a rationale to use the combination of PI3K/MTOR and MEK1/2 inhibitors against these types of tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8578